![FDA announces recall of platelet-reducing medication due to risk of clotting or other adverse cardiovascular outcomes FDA announces recall of platelet-reducing medication due to risk of clotting or other adverse cardiovascular outcomes](https://cardiovascularbusiness.com/sites/default/files/styles/twitter/public/2022-05/screen_shot_2022-05-24_at_11.24.40_am.png?h=2af9730f&itok=Bn3hX1FY)
FDA announces recall of platelet-reducing medication due to risk of clotting or other adverse cardiovascular outcomes
![These highlights do not include all the information needed to use ANAGRELIDE CAPSULES safely and effectively. See full prescribing information for ANAGRELIDE CAPSULES. ANAGRELIDE capsules, for oral useInitial U.S. Approval: 1997 These highlights do not include all the information needed to use ANAGRELIDE CAPSULES safely and effectively. See full prescribing information for ANAGRELIDE CAPSULES. ANAGRELIDE capsules, for oral useInitial U.S. Approval: 1997](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=image-4.jpg&id=639733)
These highlights do not include all the information needed to use ANAGRELIDE CAPSULES safely and effectively. See full prescribing information for ANAGRELIDE CAPSULES. ANAGRELIDE capsules, for oral useInitial U.S. Approval: 1997
Foglio illustrativo: Informazioni per il paziente Anagrelide Teva 0,5 mg capsule rigide anagrelide Medicinale equivalente Legga
![Teva Issues Voluntary Nationwide Recall of One Lot of Anagrelide Capsules, USP 0.5 mg Due to Dissolution Test Failure | FDA Teva Issues Voluntary Nationwide Recall of One Lot of Anagrelide Capsules, USP 0.5 mg Due to Dissolution Test Failure | FDA](https://www.fda.gov/files/styles/recall_image_small/public/Image%201_31.png?itok=KQKY4mSU)